Second-generation antihistamines: the risk of ventricular arrhythmias.
about
In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine.H1-antihistamines for chronic spontaneous urticariaPharmacology of antihistaminesTowards a better understanding of QT interval variabilityThe metabolic profile of second-generation antihistamines.Azelastine hydrochloride, a dual-acting anti-inflammatory ophthalmic solution, for treatment of allergic conjunctivitisEmerging treatments in the management of schizophrenia - focus on sertindolePharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug.Drug safety and efficacy evaluation of sertindole for schizophrenia.Pharmacology of antihistamines.Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios.Desloratadine: a nonsedating antihistamine.Emerging safety issues regarding long-term usage of H(1)receptor antagonists.Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations.Review of cetirizine hydrochloride for the treatment of allergic disorders.Soccer and Sudden Cardiac Death in Young Competitive Athletes: A Review.Review of desloratadine for the treatment of allergic rhinitis, chronic idiopathic urticaria and allergic inflammatory disorders.Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety.The expanding role of H1 antihistamines: a patent survey of selective and dual activity compounds 2005-2010.Safety evaluation of desloratadine in allergic rhinitis.Rupatadine: global safety evaluation in allergic rhinitis and urticaria.Antihistamines modulate the integrin signaling pathway in h9c2 rat cardiomyocytes: Possible association with cardiotoxicity.Ziprasidone and hypokalemia: a case of 2 predisposing factors for QTc prolongation without development of torsades de pointes.P21 (Cdc42/Rac)-activated kinase 1 (pak1) is associated with cardiotoxicity induced by antihistamines.Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis.Pharmacology of Antihistamines
P2860
Q21262021-1C35A82D-2421-4724-BDDB-34949BE85FD0Q24187983-89C8D419-85DF-4B99-862C-09E19431A24CQ24618798-642F2111-102F-4427-87BF-0DCEF294F9A2Q27001737-ADC970F1-7A1A-484D-8790-4A327747800AQ33963369-37B8EF05-41C5-475F-8E94-29357DACEBDCQ34122907-8859D2FB-88C0-470E-8A08-4667C676CD69Q34129334-CFBF0269-7F28-46C1-9307-5C075797A4C3Q34292689-A23EE47D-4A97-43D6-946A-09BF5EB6B7C6Q34300628-FDE65E4A-7458-420E-B862-6495AA7C69D4Q34347782-B184D1F6-822A-4BA9-B651-CDEA25C34AE3Q34982550-D3F06880-43B5-441C-B781-33A2214EF977Q35054259-F6700656-5744-426A-981E-978BF407F582Q35194475-1FAC86EF-ADDD-4DBD-8F59-0F1A318B6603Q35212261-88F7DC6E-0E9B-4E70-8928-9FD083F705DDQ35609693-5A38FA5D-8A0A-4304-9CCD-C9058862D591Q36112418-50CD8C4C-2742-4BD1-99CB-F584F729FB4DQ36301605-CB84BEEC-F276-4E41-B598-81AB8CCBD926Q36407261-C3F02C1E-0A7B-4E4E-9A7E-87E85649E537Q37780551-54DA1A91-2B09-46C0-81AD-CCCB45DFB2F1Q38097964-9DEB3750-468F-4CD9-972F-9976DE47FAC5Q38921694-8520D1AA-64CD-4299-9AE0-D893509AF143Q38937713-78A89FB0-460F-4B15-B31D-112E16F600C8Q46595623-52230980-F4BF-4B2B-9FA0-8AD59005224DQ48331323-E1E17D4A-87EF-4D2D-A952-2416BD9351DFQ49075893-382CE527-1692-4B34-A604-9F2DFF4AF6BEQ56536196-D8F53A76-A46B-4889-B313-AE0EB3C5C257
P2860
Second-generation antihistamines: the risk of ventricular arrhythmias.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Second-generation antihistamines: the risk of ventricular arrhythmias.
@ast
Second-generation antihistamines: the risk of ventricular arrhythmias.
@en
type
label
Second-generation antihistamines: the risk of ventricular arrhythmias.
@ast
Second-generation antihistamines: the risk of ventricular arrhythmias.
@en
prefLabel
Second-generation antihistamines: the risk of ventricular arrhythmias.
@ast
Second-generation antihistamines: the risk of ventricular arrhythmias.
@en
P1476
Second-generation antihistamines: the risk of ventricular arrhythmias.
@en
P2093
DuBuske LM
P304
P356
10.1016/S0149-2918(00)88286-7
P577
1999-02-01T00:00:00Z